Vaccines

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

Retrieved on: 
Wednesday, June 9, 2021
Vaccines, Medical specialties, Health, COVID-19 vaccines, Clinical trials, COVID-19 pandemic in South Africa, Lineage B.1.351, Variants of SARS-CoV-2, COVID-19, Vaccine, COVID-19 vaccine

The study provides further evidence that the T-cell response may contribute to protection from COVID-19.

Key Points: 
  • The study provides further evidence that the T-cell response may contribute to protection from COVID-19.
  • In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnsons vaccine experienced similar efficacy against the B.1.351 variant.
  • Mapping exactly how the variants impact different parts of the virus can indicate if the immune response is likely to be affected.
  • The tool can be used to study the T-cell immune response for vaccine research across COVID-19 variants., mapping across >160KSARS-CoV-2-specific antigen-TCR sequence-level data.

U.S. FDA Approves PREVNAR 20™, Pfizer’s Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

Retrieved on: 
Wednesday, June 9, 2021
Research, Medical Supplies, Infectious diseases, FDA, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Pneumonia, Medical specialties, Clinical medicine, Health care, Pneumococcal conjugate vaccine, Vaccines, Vaccination, Pneumococcal vaccine, Ruth Link-Gelles, 20-Valent Pneumococcal Conjugate Vaccine Regulatory Review, Pfizer: Breakthroughs That Change Patients’ Lives, 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE REGULATORY REVIEW, PFIZER: BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES

With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.

Key Points: 
  • With a single injection, PREVNAR 20 provides adults with strong and meaningful protection against serotypes responsible for the majority of circulating pneumococcal disease around the world.
  • Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.
  • Coverage of Next Generational Pneumococcal Conjugate Vaccines for Invasive Pneumococcal Disease in Older Adults of High-Income Countries.
  • Current and future pneumococcal conjugate vaccine serotype-specific burden in the United States adult population.

Vaxart to Present at the SVB Leerink CybeRx Series: Vaccine Forum

Retrieved on: 
Monday, June 7, 2021
Life sciences, Biotechnology, Vaccines, Medical research, Health sciences, Vaxart, Vaccination, Virology

Please contact your SVB Leerink representative to schedule virtual one-on-one meetings with Vaxart during the respective conference.

Key Points: 
  • Please contact your SVB Leerink representative to schedule virtual one-on-one meetings with Vaxart during the respective conference.
  • Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform.
  • Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury.
  • Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

Translate Bio Achieves Manufacturing Milestone Related to Influenza mRNA Vaccine Program

Retrieved on: 
Monday, June 7, 2021
Vaccines, Drugs, Vaccination, Clinical trials, COVID-19 vaccines, RNA vaccines, Medical research, Influenza vaccine, COVID-19 vaccine, Sanofi, Vaccine, Live attenuated influenza vaccine

The Phase 1 clinical trial will evaluate a monovalent influenza vaccine candidate and will inform the next steps of the mRNA-based influenza vaccine program.

Key Points: 
  • The Phase 1 clinical trial will evaluate a monovalent influenza vaccine candidate and will inform the next steps of the mRNA-based influenza vaccine program.
  • Since beginning our collaboration in June 2018, the development of mRNA vaccines for infectious diseases, including an mRNA vaccine candidate for influenza, has been a key focus of the joint development team at Translate Bio and Sanofi Pasteur, a world leader in influenza vaccines, said Ronald Renaud, chief executive officer, Translate Bio.
  • With the COVID-19 vaccine clinical program ongoing, todays announcement is another important milestone representing the significant progress weve made with vaccine platform development under the collaboration as we continue to advance multiple mRNA vaccine candidates toward clinical development.
  • Such forward-looking statements include, but are not limited to, those regarding: plans to commence a clinical trial for an influenza vaccine in the coming weeks; Translate Bios anticipated receipt of a $50 million milestone payment related to the influenza vaccine program; plans to further advance multiple mRNA vaccine candidates toward clinical development; the next steps of the mRNA-based influenza vaccine program; the expected benefits of Translate Bios collaboration with Sanofi; Translate Bios beliefs regarding the broad applicability of its technology; and Translate Bios plans, strategies and prospects for its business, including its lead development programs.

Moderna Files for Conditional Marketing Approval for its COVID-19 Vaccine in Adolescents in the European Union

Retrieved on: 
Monday, June 7, 2021
Biotechnology, FDA, Health, Other Health, Pharmaceutical, Other Science, Research, Medical devices, Infectious diseases, General Health, Hospitals, Fitness & Nutrition, Science, Clinical trials, COVID-19, COVID-19 vaccines, Clinical trials, Medicine, Vaccines, Medical research, RNA vaccines, Moderna COVID-19 vaccine, Adenoviridae, COVID-19 vaccine, Vaccine, Moderna, the COVID-19 Vaccine Moderna, Moderna, THE COVID-19 VACCINE MODERNA, MODERNA

We are pleased to announce that we have submitted for conditional marketing approval of our COVID-19 vaccine with the European Medicines Agency for use in adolescents in the European Union, said Stphane Bancel, Chief Executive Officer of Moderna.

Key Points: 
  • We are pleased to announce that we have submitted for conditional marketing approval of our COVID-19 vaccine with the European Medicines Agency for use in adolescents in the European Union, said Stphane Bancel, Chief Executive Officer of Moderna.
  • We are encouraged that the Moderna COVID-19 vaccine was highly effective at preventing COVID-19 and SARS-CoV-2 infection in adolescents.
  • In the study, no cases of COVID-19 were observed in participants who had received two doses of the Moderna COVID-19 vaccine using the primary definition.
  • The vaccine efficacy in the nearly 2,500 adolescents who received the Moderna COVID-19 vaccine was observed to be 100% when using the same case definition as in the Phase 3 COVE study in adults.

Valneva Completes Phase 3 Trial Recruitment for its Inactivated COVID-19 Vaccine Candidate

Retrieved on: 
Thursday, June 3, 2021
Clinical trials, COVID-19 vaccines, Vaccines, Drugs, Vaccination, VLA2001, Valneva SE, COVID-19 vaccine, Inactivated vaccine, COVID-19 vaccination in Norway, COVID-19 vaccination in Hungary

Over 4,000 volunteers in the United Kingdom have been randomized in the Phase 3 trial Cov-Compare (VLA2001-301), which compares Valnevas SARS-CoV-2 vaccine candidate, VLA2001, against AstraZenecas conditionally approved vaccine, Vaxzevria1.

Key Points: 
  • Over 4,000 volunteers in the United Kingdom have been randomized in the Phase 3 trial Cov-Compare (VLA2001-301), which compares Valnevas SARS-CoV-2 vaccine candidate, VLA2001, against AstraZenecas conditionally approved vaccine, Vaxzevria1.
  • Based on our Phase 1/2 clinical data and, assuming successful Phase 3 results, we believe that our inactivated vaccine can make a major contribution to the ongoing fight against the COVID-19 pandemic.
  • Valneva recently announced that it is participating in the worlds first COVID-19 vaccine booster trial in the UK2.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted vaccine candidate in clinical trials against COVID-19 in Europe.

PharmaJet: The Lancet Publication Confirms Viability of Intradermal Polio Vaccination

Retrieved on: 
Thursday, June 3, 2021
Infectious diseases, Pharmaceutical, Health, Medical devices, Clinical medicine, Medicine, Drugs, Vaccines, Vaccination, Polio, Biotechnology, Intradermal injection, Vaccine, Polio vaccine, Expanded Program on Immunization, Vaccine ingredients

Intradermal fractional dose delivery also lowers the total cost of vaccination substantially.

Key Points: 
  • Intradermal fractional dose delivery also lowers the total cost of vaccination substantially.
  • Intradermal delivery with needle and syringe is difficult for mass vaccination campaigns as it requires significant training to master, resulting in inconsistent results.
  • It requires minimal training, and virtually eliminates vaccine wastage, making it an excellent tool for mass vaccination campaigns and routine use.
  • It is ideal for delivery of intradermal polio vaccinations given its consistency and the improved immune response of 2 fractional ID doses versus 1 full intramuscular dose.

Ehave To Release Vaccine Passport As Part Of Its Medical Passport

Retrieved on: 
Thursday, June 3, 2021
Medical specialties, Clinical medicine, Medicine, Passports, Immunology, Vaccination, Immunity passport, Vaccines, Vaccine, Vaccination requirements for international travel, HPV vaccine

Ehaves Medical and Vaccine Passport will allow individuals and small businesses to easily access vaccination verification to ease implementing new safety precautions.

Key Points: 
  • Ehaves Medical and Vaccine Passport will allow individuals and small businesses to easily access vaccination verification to ease implementing new safety precautions.
  • For the millions of individuals who want to voluntarily share their vaccination information, so they know who it's safe to be around, the Ehave Dashboard could be the perfect vaccine and medical passport.
  • Mr. Kaplan continued, "We do not want to get involved in politics, but for individuals who want a Medical and Vaccine Passport, we believe the Ehave Mobile App is a potential solution."
  • All forward-looking statements included in this press release are made only as of the date of this press release.

Geneos Therapeutics Announces Clinical Updates on Personalized Cancer Vaccine Program

Retrieved on: 
Thursday, June 3, 2021
Clinical medicine, Medicine, Medical specialties, Vaccines, Cancer vaccine, Vaccination, Cancer vaccines, Biotechnology, Genomics, Tumor antigen vaccine, Cancer immunotherapy

The patient is undergoing monotherapy treatment with their personalized cancer vaccine (GNOS-PV) and pIL12 in an adjuvant setting following resection of their tumor.

Key Points: 
  • The patient is undergoing monotherapy treatment with their personalized cancer vaccine (GNOS-PV) and pIL12 in an adjuvant setting following resection of their tumor.
  • The patient received a vaccine comprising of 30 tumor antigens including 27 cancer neoantigens and 3 shared antigens.
  • "We are encouraged by the interim data from our personalized cancer vaccine program showing tumor shrinkage in combination with anti-PD1.
  • At Geneos Therapeutics, we believe that personalized therapies are the future of cancer treatment.

Coalition of Leading Organizations Launch United Effort to Drive Vaccine Uptake in Rural America

Retrieved on: 
Thursday, June 3, 2021
Medicine, Vaccination, Medical research, Medical specialties, Life sciences, Vaccine, Virology, COVID-19 vaccine, Vaccines

A key goal is to support rural community leaders and businesses as they engage with their residents in vaccine conversations.

Key Points: 
  • A key goal is to support rural community leaders and businesses as they engage with their residents in vaccine conversations.
  • The effort includes the development of a resource library for rural vaccine uptake information, led by the National Rural Health Association, including conversation starter resources, and public service announcements developed in partnership with the Ad Council.
  • The resources will be announced today at a National Rural Business Summit on COVID-19 vaccines, focused on the unique needs and opportunities in rural areas and small cities to drive vaccination rates.
  • Rural America is not homogenous, and these organizations have the diverse and necessary expertise to develop and disseminate the right messages to rural communities to move the needle on vaccination rates.